Your session is about to expire
← Back to Search
Monoclonal Antibodies
Ilumya for Psoriasis
Phase 4
Recruiting
Research Sponsored by Psoriasis Treatment Center of Central New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
Study Summary
This trial will test the effectiveness of Ilumya, a new psoriasis treatment, either alone or in combination with Halog ointment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Body surface area
Trial Design
1Treatment groups
Experimental Treatment
Group I: IlumyaExperimental Treatment1 Intervention
Ilumya 100mg subcutaneous at weeks 0, 4 and 16.
Find a Location
Who is running the clinical trial?
Psoriasis Treatment Center of Central New JerseyLead Sponsor
14 Previous Clinical Trials
417 Total Patients Enrolled
13 Trials studying Psoriasis
377 Patients Enrolled for Psoriasis
Sun Pharmaceutical Industries LimitedIndustry Sponsor
64 Previous Clinical Trials
13,486 Total Patients Enrolled
13 Trials studying Psoriasis
2,710 Patients Enrolled for Psoriasis
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger